Review

cu cpt4a (MedChemExpress)

Name: cu cpt4a
Brand: MedChemExpress
Rating: 94 (11 reviews)

MedChemExpress is a verified supplier

MedChemExpress manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MedChemExpress cu cpt4a

F12 medium sensitizes lung cancer cells to iron-dependent lipid peroxidation . ( A, B ) Quantification by flow cytometry of oxidized BODIPY-C11 fluorescence in A549 (A) or H838 (B) cells that were cultured in RPMI or F12 medium and treated with 100 μM BSO or vehicle for 24 h. ( C ) Dose response curves for F12-cultured A549 and H838 cells treated with BSO in combination with 5 μM liproxstatin-1 (LIP-1), 5 μM ferrostatin-1 (FER-1) or 50 μM α-tocopherol (α-toco) for 72 h. ( D ) Dose response curves for F12-cultured A549 or H838 cells treated with BSO in combination with 5 μM deferoxamine (DFO) for A549 cells and 9 μM for H838 cells for 72 h. ( E ) Dose response curves for F12-cultured A549 or H838 cells treated with BSO in combination with 5 μM necrostatin-1 (NEC-1) or 10 μM ZVAD-FMK (ZVAD) for 72 h. ( F ) Dose response curves for F12-cultured A549 or H838 cells treated with BSO in combination with 4 μg/mL certolizumab (CER), 15 <t>μM</t> <t>CU-CPT4a</t> (C4a), 3 μM resatorvid (RST), or 50 μM necrostatin-1 (NEC-1) for 72 h (ND, not done). Dose response curves were normalized against the mean of the untreated samples for each condition. n = 3 replicates for all datapoints, error bars show SEM. ∗∗∗∗P < 0.0001.

Cu Cpt4a, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cu cpt4a/product/MedChemExpress
Average 94 stars, based on 11 article reviews

cu cpt4a - by Bioz Stars, 2026-03

94/100 stars

Images

1) Product Images from "Amino acid restriction sensitizes lung cancer cells to ferroptosis via GCN2-dependent activation of the integrated stress response"

Article Title: Amino acid restriction sensitizes lung cancer cells to ferroptosis via GCN2-dependent activation of the integrated stress response

Journal: Redox Biology

doi: 10.1016/j.redox.2025.103988

Figure Legend Snippet: F12 medium sensitizes lung cancer cells to iron-dependent lipid peroxidation . ( A, B ) Quantification by flow cytometry of oxidized BODIPY-C11 fluorescence in A549 (A) or H838 (B) cells that were cultured in RPMI or F12 medium and treated with 100 μM BSO or vehicle for 24 h. ( C ) Dose response curves for F12-cultured A549 and H838 cells treated with BSO in combination with 5 μM liproxstatin-1 (LIP-1), 5 μM ferrostatin-1 (FER-1) or 50 μM α-tocopherol (α-toco) for 72 h. ( D ) Dose response curves for F12-cultured A549 or H838 cells treated with BSO in combination with 5 μM deferoxamine (DFO) for A549 cells and 9 μM for H838 cells for 72 h. ( E ) Dose response curves for F12-cultured A549 or H838 cells treated with BSO in combination with 5 μM necrostatin-1 (NEC-1) or 10 μM ZVAD-FMK (ZVAD) for 72 h. ( F ) Dose response curves for F12-cultured A549 or H838 cells treated with BSO in combination with 4 μg/mL certolizumab (CER), 15 μM CU-CPT4a (C4a), 3 μM resatorvid (RST), or 50 μM necrostatin-1 (NEC-1) for 72 h (ND, not done). Dose response curves were normalized against the mean of the untreated samples for each condition. n = 3 replicates for all datapoints, error bars show SEM. ∗∗∗∗P < 0.0001.

Techniques Used: Flow Cytometry, Fluorescence, Cell Culture

Image Search Results

Journal: Redox Biology

Article Title: Amino acid restriction sensitizes lung cancer cells to ferroptosis via GCN2-dependent activation of the integrated stress response

doi: 10.1016/j.redox.2025.103988

Figure Lengend Snippet: F12 medium sensitizes lung cancer cells to iron-dependent lipid peroxidation . ( A, B ) Quantification by flow cytometry of oxidized BODIPY-C11 fluorescence in A549 (A) or H838 (B) cells that were cultured in RPMI or F12 medium and treated with 100 μM BSO or vehicle for 24 h. ( C ) Dose response curves for F12-cultured A549 and H838 cells treated with BSO in combination with 5 μM liproxstatin-1 (LIP-1), 5 μM ferrostatin-1 (FER-1) or 50 μM α-tocopherol (α-toco) for 72 h. ( D ) Dose response curves for F12-cultured A549 or H838 cells treated with BSO in combination with 5 μM deferoxamine (DFO) for A549 cells and 9 μM for H838 cells for 72 h. ( E ) Dose response curves for F12-cultured A549 or H838 cells treated with BSO in combination with 5 μM necrostatin-1 (NEC-1) or 10 μM ZVAD-FMK (ZVAD) for 72 h. ( F ) Dose response curves for F12-cultured A549 or H838 cells treated with BSO in combination with 4 μg/mL certolizumab (CER), 15 μM CU-CPT4a (C4a), 3 μM resatorvid (RST), or 50 μM necrostatin-1 (NEC-1) for 72 h (ND, not done). Dose response curves were normalized against the mean of the untreated samples for each condition. n = 3 replicates for all datapoints, error bars show SEM. ∗∗∗∗P < 0.0001.

Article Snippet: Drugs used were auranofin (A6733; Sigma-Aldrich), α-tocopherol (T3251; Sigma-Aldrich), bafilomycin A1 (SML1661; Sigma-Aldrich), certolizumab pegol (HYP9953; MedChemExpress), chloroquine (C6628; Sigma-Aldrich), CU-CPT4A (HY-108473; MedChemExpress), deferoxamine (D9533; Sigma-Aldrich), erastin (e7781; Sigma Aldrich), FCCP (Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone) (HY-100410; MedChemExpress), ferrostatin-1 (SML0583; Sigma-Aldrich), l -buthionine-sulfoximine (b2515; Sigma-Aldrich), mito-TEMPO (HY–W001187; MedChemExpress), necrostatin-1 (N9037; Sigma-Aldrich), liproxstatin-1 (SML1414; Sigma-Aldrich), oligomycin (HY–N6782; MedChemExpress), puromycin dihydrochloride (A1113803; Gibco), rotenone (HY–B1756; MedChemExpress), RSL3 (SML2234; Sigma-Aldrich), resatorvid (HY-11109; MedChemExpress), and Z-VAD-FMK (V116; Sigma-Aldrich).

Techniques: Flow Cytometry, Fluorescence, Cell Culture

Radiotherapy (RT) enhanced cytosolic dsRNA accumulation for TLR3-mediated type I IFN production. (A) HCT116 cells were irradiated for 24 hours, and then RNA was extracted for electrophoresis (7.5% polyacrylamide gel electrophoresis). HCT116 cells were irradiated for 24 and 48 hours, and the content of cytosolic dsRNA was measured by dsRNA ELISA kit (n=3). *p<0.05, **p<0.01. One-way ANOVA test. (B) SW480 cells were irradiated with 5 Gy for 24 hours, and the level of dsRNA was observed by immunofluorescence staining. *p<0.05 Unpaired t-test. (C) SW480 cells were treated with conditioned medium for 24 hours and then examined by qRT-PCR (n=3). The conditioned medium was collected from irradiated cells and then incubated with RNase A and RNase III for 2 hours. The level of IFNβ1 was analyzed by qRT-PCR (n=3). ***p<0.001. One-way ANOVA test. (D) SW480 cells were treated with conditioned medium for 24 hours and then examined by qRT-PCR (n=3). The conditioned medium was collected from irradiated cells and then incubated with RNase A and RNase III for 2 hours. The level of CXCL10 was analyzed by qRT-PCR (n=3). **p<0.01. One-way ANOVA test. (E) Representative images of cytosolic dsRNA in pre-neoCRT biopsies and post-neoCRT surgical tissues. (F) The correlation between cytosolic dsRNA and tumor IFNβ expression was measured (non-linear regression model, p=0.0012, r =0.2794, n=131). (G) SW480 cells were infected with lentivirus carrying shRNA against RIG1, MDA5 and MAVS. The knockdown efficacy was examined by western blotting. (H) SW480 shNC , SW480 shRIG1 , SW480 shTLR3 , SW480 shMDA5 and SW480 shMAVS cells were irradiated with 5 Gy. After 24 hours, the cells were harvested, and the mRNA levels of IFNβ1 and CXCL10 were examined by qRT-PCR (n=3). *p<0.05, **p<0.01. One-way ANOVA test. (I) HCT116 cells were infected with lentivirus carrying shRNA against TLR3. The knockdown efficacy was measured by immunoblotting. HCT116 shNC , HCT116 shTLR3#1 and HCT116 shTLR3#2 cells were irradiated with 5 and 10 Gy. After 24 hours, the cells were harvested, and the mRNA levels of IFNβ1 and CXCL10 were examined by qRT-PCR (n=3). **p<0.01, ***p<0.001. One-way ANOVA test. (J) HCT116 shNC and HCT116 shTLR3 cells were with or without irradiation with 5 Gy. After 24 hours, CFSE-labeled SupT1 T cells were seeded in the upper wells, and the migrated T cells were examined by flow cytometry (n=3). **p<0.01, ***p<0.001. One-way ANOVA test. (K) HCT116 isogenic TLR3 knockout cells (HCT116-TLR3 KO ) constructed with TLR3 gRNA and HCT115-WT cells constructed with non-targeting (NT) gRNA. HCT116-WT and HCT116-TLR3 KO cells were irradiated with 5 Gy and harvested after 24 hours. The levels of IFNβ1 were analyzed by qRT-PCR (n=3). *p<0.05. One-way ANOVA test. ANOVA, analysis of variance; CFSE, Carboxyfluorescein succinimidyl ester; qRT-PCR, quantitated by real-time PCR.

Journal: Journal for Immunotherapy of Cancer

Article Title: Colorectal cancer-specific IFNβ delivery overcomes dysfunctional dsRNA-mediated type I interferon signaling to increase the abscopal effect of radiotherapy

doi: 10.1136/jitc-2023-008515

Figure Lengend Snippet: Radiotherapy (RT) enhanced cytosolic dsRNA accumulation for TLR3-mediated type I IFN production. (A) HCT116 cells were irradiated for 24 hours, and then RNA was extracted for electrophoresis (7.5% polyacrylamide gel electrophoresis). HCT116 cells were irradiated for 24 and 48 hours, and the content of cytosolic dsRNA was measured by dsRNA ELISA kit (n=3). *p<0.05, **p<0.01. One-way ANOVA test. (B) SW480 cells were irradiated with 5 Gy for 24 hours, and the level of dsRNA was observed by immunofluorescence staining. *p<0.05 Unpaired t-test. (C) SW480 cells were treated with conditioned medium for 24 hours and then examined by qRT-PCR (n=3). The conditioned medium was collected from irradiated cells and then incubated with RNase A and RNase III for 2 hours. The level of IFNβ1 was analyzed by qRT-PCR (n=3). ***p<0.001. One-way ANOVA test. (D) SW480 cells were treated with conditioned medium for 24 hours and then examined by qRT-PCR (n=3). The conditioned medium was collected from irradiated cells and then incubated with RNase A and RNase III for 2 hours. The level of CXCL10 was analyzed by qRT-PCR (n=3). **p<0.01. One-way ANOVA test. (E) Representative images of cytosolic dsRNA in pre-neoCRT biopsies and post-neoCRT surgical tissues. (F) The correlation between cytosolic dsRNA and tumor IFNβ expression was measured (non-linear regression model, p=0.0012, r =0.2794, n=131). (G) SW480 cells were infected with lentivirus carrying shRNA against RIG1, MDA5 and MAVS. The knockdown efficacy was examined by western blotting. (H) SW480 shNC , SW480 shRIG1 , SW480 shTLR3 , SW480 shMDA5 and SW480 shMAVS cells were irradiated with 5 Gy. After 24 hours, the cells were harvested, and the mRNA levels of IFNβ1 and CXCL10 were examined by qRT-PCR (n=3). *p<0.05, **p<0.01. One-way ANOVA test. (I) HCT116 cells were infected with lentivirus carrying shRNA against TLR3. The knockdown efficacy was measured by immunoblotting. HCT116 shNC , HCT116 shTLR3#1 and HCT116 shTLR3#2 cells were irradiated with 5 and 10 Gy. After 24 hours, the cells were harvested, and the mRNA levels of IFNβ1 and CXCL10 were examined by qRT-PCR (n=3). **p<0.01, ***p<0.001. One-way ANOVA test. (J) HCT116 shNC and HCT116 shTLR3 cells were with or without irradiation with 5 Gy. After 24 hours, CFSE-labeled SupT1 T cells were seeded in the upper wells, and the migrated T cells were examined by flow cytometry (n=3). **p<0.01, ***p<0.001. One-way ANOVA test. (K) HCT116 isogenic TLR3 knockout cells (HCT116-TLR3 KO ) constructed with TLR3 gRNA and HCT115-WT cells constructed with non-targeting (NT) gRNA. HCT116-WT and HCT116-TLR3 KO cells were irradiated with 5 Gy and harvested after 24 hours. The levels of IFNβ1 were analyzed by qRT-PCR (n=3). *p<0.05. One-way ANOVA test. ANOVA, analysis of variance; CFSE, Carboxyfluorescein succinimidyl ester; qRT-PCR, quantitated by real-time PCR.

Article Snippet: HCT116 cells were treated with 2.5 μg/mL poly (I:C) (Sigma, Missouri, USA) or 10 μM selective TLR3 inhibitor CU-CPT4a (Tocris, Pennsylvania, USA) for 24 hours.

Techniques: Irradiation, Electrophoresis, Polyacrylamide Gel Electrophoresis, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining, Quantitative RT-PCR, Incubation, Expressing, Infection, shRNA, Knockdown, Western Blot, Labeling, Flow Cytometry, Knock-Out, Construct, Real-time Polymerase Chain Reaction

TLR3 and IFNAR1 are indispensable for irradiation-induced type I IFN and CXCL10 production. (A) SW480 cells were irradiated and treated with 2.5 µg/mL poly (I:C) and 10 µM TLR3 inhibitor together for 24 hours. The mRNA levels of TLR3 , IFNβ1, CXCL10 and MX1 were analyzed by qRT-PCR (n=3). *p<0.05, **p<0.01 and ***p<0.001. One-way ANOVA test. (B) SW480 cells were irradiated and treated with 2.5 µg/mL poly (I:C) and 10 µM TLR3 inhibitor together for 24 hours. The protein levels of p-IRF3, IRF3, p-STAT1, and STAT1 were examined by immunoblotting. *p<0.05, **p<0.01, ***p<0.001. One-way ANOVA test. (C) SW480 cells were transfected with pCMV6-vector, pCMV-TLR3-WT, or pCMV-TLR3-L412F for 24 hours and then irradiated with 5 Gy. After 24 hours, we analyzed the protein level by immunoblotting. (D) The quantification of p-IRF3/IRF3 and p-STAT1/STAT1 is shown. *p<0.05, **p<0.01. One-way ANOVA test. (E) HCT116 cells were infected with lentivirus carrying shRNA against IFNAR. The knockdown efficacy was measured by immunoblotting. HCT116 shNC , HCT116 shIFNAR1#1 and HCT116 shIFNAR1#2 cells were irradiated with 5 and 10 Gy. After 24 hours, the cells were harvested, and the mRNA level of CXCL10 was examined by qRT-PCR. ***p<0.001. One-way ANOVA test. (F) HCT116 shNC and HCT116 shIFNAR1#2 cells were irradiated with 5 Gy. After 24 hours, conditioned medium was harvested to analyze the level of CXCL10 by ELISA. ***p<0.001. One-way ANOVA test. ANOVA, analysis of variance; qRT-PCR, quantitated by real-time PCR.

Journal: Journal for Immunotherapy of Cancer

Article Title: Colorectal cancer-specific IFNβ delivery overcomes dysfunctional dsRNA-mediated type I interferon signaling to increase the abscopal effect of radiotherapy

doi: 10.1136/jitc-2023-008515

Figure Lengend Snippet: TLR3 and IFNAR1 are indispensable for irradiation-induced type I IFN and CXCL10 production. (A) SW480 cells were irradiated and treated with 2.5 µg/mL poly (I:C) and 10 µM TLR3 inhibitor together for 24 hours. The mRNA levels of TLR3 , IFNβ1, CXCL10 and MX1 were analyzed by qRT-PCR (n=3). *p<0.05, **p<0.01 and ***p<0.001. One-way ANOVA test. (B) SW480 cells were irradiated and treated with 2.5 µg/mL poly (I:C) and 10 µM TLR3 inhibitor together for 24 hours. The protein levels of p-IRF3, IRF3, p-STAT1, and STAT1 were examined by immunoblotting. *p<0.05, **p<0.01, ***p<0.001. One-way ANOVA test. (C) SW480 cells were transfected with pCMV6-vector, pCMV-TLR3-WT, or pCMV-TLR3-L412F for 24 hours and then irradiated with 5 Gy. After 24 hours, we analyzed the protein level by immunoblotting. (D) The quantification of p-IRF3/IRF3 and p-STAT1/STAT1 is shown. *p<0.05, **p<0.01. One-way ANOVA test. (E) HCT116 cells were infected with lentivirus carrying shRNA against IFNAR. The knockdown efficacy was measured by immunoblotting. HCT116 shNC , HCT116 shIFNAR1#1 and HCT116 shIFNAR1#2 cells were irradiated with 5 and 10 Gy. After 24 hours, the cells were harvested, and the mRNA level of CXCL10 was examined by qRT-PCR. ***p<0.001. One-way ANOVA test. (F) HCT116 shNC and HCT116 shIFNAR1#2 cells were irradiated with 5 Gy. After 24 hours, conditioned medium was harvested to analyze the level of CXCL10 by ELISA. ***p<0.001. One-way ANOVA test. ANOVA, analysis of variance; qRT-PCR, quantitated by real-time PCR.

Article Snippet: HCT116 cells were treated with 2.5 μg/mL poly (I:C) (Sigma, Missouri, USA) or 10 μM selective TLR3 inhibitor CU-CPT4a (Tocris, Pennsylvania, USA) for 24 hours.

Techniques: Irradiation, Quantitative RT-PCR, Western Blot, Transfection, Plasmid Preparation, Infection, shRNA, Knockdown, Enzyme-linked Immunosorbent Assay, Real-time Polymerase Chain Reaction

$TLR3 signaling is important for type I IFN and CXCL10 production to recruit intratumoral TILs in vivo. (A) Tumor growth of CT26-driven colon carcinoma established in BALB/c mice (n=8/group) that were treated with radiotherapy (5 Gy for two fractions) or radiotherapy/TLR3 inhibitor (0.4 mg/kg TLR3 inhibitor 1 hour before and after irradiation). Tumor volume was recorded every 3 days (mean±SE). *p<0.05. The resected tumor tissues were harvested on day 25 for further analysis. (B) The representative image of cytosolic dsRNA in resected tumor tissues which was observed by anti-dsRNA (J2 clone) immunofluorescence staining (n=3). The cytosolic dsRNA fluorescence intensity was examined. ***p<0.001. One-way ANOVA test. (C) Resected tumors were extracted, and the mRNA levels of Ifnβ1 and Cxcl10 were analyzed by qRT-PCR (n=4). *p<0.05. One-way ANOVA test. (D) Resected tumors were extracted, and the mRNA levels of Mx1 and Cxcr3 were analyzed by qRT-PCR (n=4). *p<0.05. One-way ANOVA test. (E) The representative images of CD3 + TILs and CD8a + TILs which were analyzed by immunohistochemistry. The density of CD3 + TILs and CD8a + TILs was counted under high-power-field microscopy (n=6). **p<0.01, ***p<0.001. One-way ANOVA test. (F) The representative images of GzmB + CD8a + TILs which were analyzed by immunofluorescence staining. The density of GzmB + CD8a + TILs was counted under high-power-field microscopy (n=6). **p<0.01, ***p<0.001. One-way ANOVA test. (G) The representative images of Cxcr3 + CD8a + TILs and Cxcr3 + CD11c + DCs and dsRNA which were by immunofluorescence staining. The density of Cxcr3 + CD8a + TILs and Cxcr3 + CD11c + DCs was counted under high-power-field microscopy (n=6). **p<0.01, ***p<0.001. One-way ANOVA test. (H) The resected tumors were extracted and analyzed by immunoblotting (n=3). Quantitative analysis of the immunoblotting results. ***p<0.001. One-way ANOVA test. ANOVA, analysis of variance; qRT-PCR, quantitated by real-time PCR; TIL, tumor-infiltrating lymphocyte.$

Journal: Journal for Immunotherapy of Cancer

Article Title: Colorectal cancer-specific IFNβ delivery overcomes dysfunctional dsRNA-mediated type I interferon signaling to increase the abscopal effect of radiotherapy

doi: 10.1136/jitc-2023-008515

Figure Lengend Snippet: TLR3 signaling is important for type I IFN and CXCL10 production to recruit intratumoral TILs in vivo. (A) Tumor growth of CT26-driven colon carcinoma established in BALB/c mice (n=8/group) that were treated with radiotherapy (5 Gy for two fractions) or radiotherapy/TLR3 inhibitor (0.4 mg/kg TLR3 inhibitor 1 hour before and after irradiation). Tumor volume was recorded every 3 days (mean±SE). *p<0.05. The resected tumor tissues were harvested on day 25 for further analysis. (B) The representative image of cytosolic dsRNA in resected tumor tissues which was observed by anti-dsRNA (J2 clone) immunofluorescence staining (n=3). The cytosolic dsRNA fluorescence intensity was examined. ***p<0.001. One-way ANOVA test. (C) Resected tumors were extracted, and the mRNA levels of Ifnβ1 and Cxcl10 were analyzed by qRT-PCR (n=4). *p<0.05. One-way ANOVA test. (D) Resected tumors were extracted, and the mRNA levels of Mx1 and Cxcr3 were analyzed by qRT-PCR (n=4). *p<0.05. One-way ANOVA test. (E) The representative images of CD3 + TILs and CD8a + TILs which were analyzed by immunohistochemistry. The density of CD3 + TILs and CD8a + TILs was counted under high-power-field microscopy (n=6). **p<0.01, ***p<0.001. One-way ANOVA test. (F) The representative images of GzmB + CD8a + TILs which were analyzed by immunofluorescence staining. The density of GzmB + CD8a + TILs was counted under high-power-field microscopy (n=6). **p<0.01, ***p<0.001. One-way ANOVA test. (G) The representative images of Cxcr3 + CD8a + TILs and Cxcr3 + CD11c + DCs and dsRNA which were by immunofluorescence staining. The density of Cxcr3 + CD8a + TILs and Cxcr3 + CD11c + DCs was counted under high-power-field microscopy (n=6). **p<0.01, ***p<0.001. One-way ANOVA test. (H) The resected tumors were extracted and analyzed by immunoblotting (n=3). Quantitative analysis of the immunoblotting results. ***p<0.001. One-way ANOVA test. ANOVA, analysis of variance; qRT-PCR, quantitated by real-time PCR; TIL, tumor-infiltrating lymphocyte.

Article Snippet: HCT116 cells were treated with 2.5 μg/mL poly (I:C) (Sigma, Missouri, USA) or 10 μM selective TLR3 inhibitor CU-CPT4a (Tocris, Pennsylvania, USA) for 24 hours.

Techniques: In Vivo, Irradiation, Immunofluorescence, Staining, Fluorescence, Quantitative RT-PCR, Immunohistochemistry, Microscopy, Western Blot, Real-time Polymerase Chain Reaction

Patients with the TLR3 loss-of-function variant (L412F/rs3775291) were associated with less infiltration of CD8 + TILs, poor therapeutic response and survival outcome. (A) Kaplan-Meier curves for 5-year DFS in individuals with high or low CD8 + TILs density in the post-neoCRT surgical tissues of LARC patient who received neoCRT in a retrospective study (log-rank p=0.042, n=111). (B) Kaplan-Meier curves for 5-year DFS in individuals with wild-type or defective TLR3 variant (L412F/rs3775291) in the cohort receiving neoCRT treatment (log-rank p=0.011, n=118). (C) Representative image of CD8 + TILs within the TME in wild-type and mutant (L412F/rs3775291) TLR3 before and after neoCRT treatment. The density of CD8 + TILs within the TME in the post-neoCRT tissues is shown (unpaired t-test, p=0.0216, n=100). (D) Kaplan-Meier curves for 5-year DFS in individuals with TLR3 variant (L412F/rs3775291) and high/low CD8 + TILs density in the cohort receiving neoCRT treatment (log-rank p=0.0063, n=100). (E) The forest plot of multivariate analysis including pN stage, TRG, TLR3 variant, CD8 counts and TLR3/CD8 (n=100). Multivariate Cox analysis. (F) Scheme of advanced CRC patient enrolment (n=24). T0: diagnosis day; T1: patients received 1 week of treatment; T2: surgery day. (G) The level of type I signatures including IFNα2, IFNβ1 and CXCL10 was measured in the serum of patients with advanced CRC carrying wild-type TLR3 (n=9, paired t-test). *p<0.05 and **p<0.01. (H) The density of CD8 + TILs within TME was measured in the patients with advanced CRC carrying wild-type TLR3 (n=9, paired t test). *p<0.05. (I) The level of type I signatures including IFNα2, IFNβ1 and CXCL10 was measured in the serum of patients with advanced CRC carrying mutant TLR3 (n=15, paired t-test). (J) The density of CD8 + TILs within TME was measured in the patients with advanced CRC carrying mutant TLR3 (n=15, paired t test). (K) The association between the level of tumor-intrinsic CXCL10 mRNA level and the response to neoCRT was evaluated in the external dataset retrieved from NCBI GEO dataset (GSE46862). MI: minimal response (TRG1); MO: moderate response (TRG2); NT: near complete response (TRG3) and TO: total response (TRG4). (n=64, one-way ANOVA test). (L) Kaplan-Meier curves for DFS in patients with colorectal cancer with high or low CXCL10 mRNA (cut-off=median TPM), which was retrieved form the GEPIA database (Gene Expression Profiling Interactive Analysis, http://gepia.cancer-pku.cn/ ). Log-rank test (n=270). ANOVA, analysis of variance; CRC, colorectal cancer; DFS, analysis of variance; TILs, tumor-infiltrating lymphocytes; TME, tumor microenvironment.

Journal: Journal for Immunotherapy of Cancer

Article Title: Colorectal cancer-specific IFNβ delivery overcomes dysfunctional dsRNA-mediated type I interferon signaling to increase the abscopal effect of radiotherapy

doi: 10.1136/jitc-2023-008515

Figure Lengend Snippet: Patients with the TLR3 loss-of-function variant (L412F/rs3775291) were associated with less infiltration of CD8 + TILs, poor therapeutic response and survival outcome. (A) Kaplan-Meier curves for 5-year DFS in individuals with high or low CD8 + TILs density in the post-neoCRT surgical tissues of LARC patient who received neoCRT in a retrospective study (log-rank p=0.042, n=111). (B) Kaplan-Meier curves for 5-year DFS in individuals with wild-type or defective TLR3 variant (L412F/rs3775291) in the cohort receiving neoCRT treatment (log-rank p=0.011, n=118). (C) Representative image of CD8 + TILs within the TME in wild-type and mutant (L412F/rs3775291) TLR3 before and after neoCRT treatment. The density of CD8 + TILs within the TME in the post-neoCRT tissues is shown (unpaired t-test, p=0.0216, n=100). (D) Kaplan-Meier curves for 5-year DFS in individuals with TLR3 variant (L412F/rs3775291) and high/low CD8 + TILs density in the cohort receiving neoCRT treatment (log-rank p=0.0063, n=100). (E) The forest plot of multivariate analysis including pN stage, TRG, TLR3 variant, CD8 counts and TLR3/CD8 (n=100). Multivariate Cox analysis. (F) Scheme of advanced CRC patient enrolment (n=24). T0: diagnosis day; T1: patients received 1 week of treatment; T2: surgery day. (G) The level of type I signatures including IFNα2, IFNβ1 and CXCL10 was measured in the serum of patients with advanced CRC carrying wild-type TLR3 (n=9, paired t-test). *p<0.05 and **p<0.01. (H) The density of CD8 + TILs within TME was measured in the patients with advanced CRC carrying wild-type TLR3 (n=9, paired t test). *p<0.05. (I) The level of type I signatures including IFNα2, IFNβ1 and CXCL10 was measured in the serum of patients with advanced CRC carrying mutant TLR3 (n=15, paired t-test). (J) The density of CD8 + TILs within TME was measured in the patients with advanced CRC carrying mutant TLR3 (n=15, paired t test). (K) The association between the level of tumor-intrinsic CXCL10 mRNA level and the response to neoCRT was evaluated in the external dataset retrieved from NCBI GEO dataset (GSE46862). MI: minimal response (TRG1); MO: moderate response (TRG2); NT: near complete response (TRG3) and TO: total response (TRG4). (n=64, one-way ANOVA test). (L) Kaplan-Meier curves for DFS in patients with colorectal cancer with high or low CXCL10 mRNA (cut-off=median TPM), which was retrieved form the GEPIA database (Gene Expression Profiling Interactive Analysis, http://gepia.cancer-pku.cn/ ). Log-rank test (n=270). ANOVA, analysis of variance; CRC, colorectal cancer; DFS, analysis of variance; TILs, tumor-infiltrating lymphocytes; TME, tumor microenvironment.

Article Snippet: HCT116 cells were treated with 2.5 μg/mL poly (I:C) (Sigma, Missouri, USA) or 10 μM selective TLR3 inhibitor CU-CPT4a (Tocris, Pennsylvania, USA) for 24 hours.

Techniques: Variant Assay, Clinical Proteomics, Mutagenesis, Biomarker Discovery, Gene Expression

$Local IFNβ1 overcomes the impact of TLR3 dysfunction and significantly enhances the therapeutic efficacy of radiotherapy. (A) Tumor growth of CT26-driven colon carcinoma established in BALB/c mice (n=5/group) that were treated with local radiotherapy (5 Gy for two fractions), radiotherapy/TLR3 inhibitor (0.4 mg/kg TLR3 inhibitor 1 hour before and after irradiation), and radiotherapy/TLR3 inhibitor/IFNβ (10,000 U/mouse). (B) Tumor growth was recorded as the mean tumor volume±SEM (n=5). *p<0.05. (C) The survival time was recorded every 3 days, and the mice were sacrificed if the average tumor diameter reached 20 mm. (D) Diagram of the novel engineered AAV-IFNβ with a CRC-specific promoter and the administration protocol. A total of 3×10 5 CT26 cells were subcutaneously injected into the right leg, and 2×10 5 CT26 cells were subcutaneously injected into the left back 2 days later. Local radiotherapy was given on days 10 and 13, and AAV (1×10 8 vg in 50 µL PBS, intramuscular injection) was administered on days 9, 13, 16 and 20. AAV-Vec: empty AAV vector with CRC-specific CEA promoter; CEAp: CEA promoter; gray box: inverted terminal repeats (ITR). (E) CT26 tumor-bearing mice (n=5–6/group) received AAV and local radiotherapy (5 Gy for two fractions) on the indicated days. Tumor volume was measured every 3 days, and tumors were harvested on day 31. **p<0.01, ***p<0.001. CR: complete response. (F) The resected irradiated tumors were weighed (n=3–5, variable due to CR). **p<0.01, ***p<0.001. One-way ANOVA test. (G) The tumor-infiltrating DCs and CD8 + immune cells in resected primary tumors were evaluated by immunofluorescence staining. (H) Quantification of tumor-infiltrating CD8 + immune cells in resected primary tumors. *p<0.05, **p<0.01. One-way ANOVA test. (I) Quantification of tumor-infiltrating CD11c + DCs in resected primary tumors. *p<0.05, **p<0.01. One-way ANOVA test. (J) The tumor volume of non-irradiated tumors (abscopal tumors) was measured every 3 days, and the tumors were harvested on Day 31. *p<0.05, **p<0.01. (K) The resected abscopal tumors were weighed (n=4–5, variable due to CR). **p<0.01, ***p<0.001. One-way ANOVA test. (L) The tumor-infiltrating DCs and CD8 + immune cells in resected abscopal tumors were evaluated by immunofluorescence staining. (M) Quantification of tumor-infiltrating CD8 + immune cells in resected abscopal tumors. *p<0.05, **p<0.01. One-way ANOVA test. (N) Quantification of tumor-infiltrating CD11c + DCs in resected abscopal tumors. *p<0.05 and **p<0.01. One-way ANOVA test. ANOVA, analysis of variance.$

Journal: Journal for Immunotherapy of Cancer

Article Title: Colorectal cancer-specific IFNβ delivery overcomes dysfunctional dsRNA-mediated type I interferon signaling to increase the abscopal effect of radiotherapy

doi: 10.1136/jitc-2023-008515

Figure Lengend Snippet: Local IFNβ1 overcomes the impact of TLR3 dysfunction and significantly enhances the therapeutic efficacy of radiotherapy. (A) Tumor growth of CT26-driven colon carcinoma established in BALB/c mice (n=5/group) that were treated with local radiotherapy (5 Gy for two fractions), radiotherapy/TLR3 inhibitor (0.4 mg/kg TLR3 inhibitor 1 hour before and after irradiation), and radiotherapy/TLR3 inhibitor/IFNβ (10,000 U/mouse). (B) Tumor growth was recorded as the mean tumor volume±SEM (n=5). *p<0.05. (C) The survival time was recorded every 3 days, and the mice were sacrificed if the average tumor diameter reached 20 mm. (D) Diagram of the novel engineered AAV-IFNβ with a CRC-specific promoter and the administration protocol. A total of 3×10 5 CT26 cells were subcutaneously injected into the right leg, and 2×10 5 CT26 cells were subcutaneously injected into the left back 2 days later. Local radiotherapy was given on days 10 and 13, and AAV (1×10 8 vg in 50 µL PBS, intramuscular injection) was administered on days 9, 13, 16 and 20. AAV-Vec: empty AAV vector with CRC-specific CEA promoter; CEAp: CEA promoter; gray box: inverted terminal repeats (ITR). (E) CT26 tumor-bearing mice (n=5–6/group) received AAV and local radiotherapy (5 Gy for two fractions) on the indicated days. Tumor volume was measured every 3 days, and tumors were harvested on day 31. **p<0.01, ***p<0.001. CR: complete response. (F) The resected irradiated tumors were weighed (n=3–5, variable due to CR). **p<0.01, ***p<0.001. One-way ANOVA test. (G) The tumor-infiltrating DCs and CD8 + immune cells in resected primary tumors were evaluated by immunofluorescence staining. (H) Quantification of tumor-infiltrating CD8 + immune cells in resected primary tumors. *p<0.05, **p<0.01. One-way ANOVA test. (I) Quantification of tumor-infiltrating CD11c + DCs in resected primary tumors. *p<0.05, **p<0.01. One-way ANOVA test. (J) The tumor volume of non-irradiated tumors (abscopal tumors) was measured every 3 days, and the tumors were harvested on Day 31. *p<0.05, **p<0.01. (K) The resected abscopal tumors were weighed (n=4–5, variable due to CR). **p<0.01, ***p<0.001. One-way ANOVA test. (L) The tumor-infiltrating DCs and CD8 + immune cells in resected abscopal tumors were evaluated by immunofluorescence staining. (M) Quantification of tumor-infiltrating CD8 + immune cells in resected abscopal tumors. *p<0.05, **p<0.01. One-way ANOVA test. (N) Quantification of tumor-infiltrating CD11c + DCs in resected abscopal tumors. *p<0.05 and **p<0.01. One-way ANOVA test. ANOVA, analysis of variance.

Article Snippet: HCT116 cells were treated with 2.5 μg/mL poly (I:C) (Sigma, Missouri, USA) or 10 μM selective TLR3 inhibitor CU-CPT4a (Tocris, Pennsylvania, USA) for 24 hours.

Techniques: Drug discovery, Irradiation, Injection, Plasmid Preparation, Immunofluorescence, Staining

Cancer-intrinsic IFNβ1 expression by AAV transduction significantly reshaped cancer immunogenicity to enhance RT-induced immunity. (A) The tumor-infiltrating CD8 + CD3 + CD45 + T cells were analyzed by flow cytometry (one-way ANOVA test, n=3–5). *p<0.05, **p<0.01. One-way ANOVA test. (B) The tumor-infiltrating CD44 + CD62L - CD8 + CD3 + CD45 + T EM cells were analyzed by flow cytometry (one-way ANOVA test, n=3–5). *p<0.05, **p<0.01. One-way ANOVA test. (C) The tumor-infiltrating CD11c + MHC-II+ DCs were analyzed by flow cytometry (one-way ANOVA test, n=3–5). *p<0.05, **p<0.01. One-way ANOVA test. (D) The tumor-infiltrating IFNγ + CD8 + CD3 + CD45 + T cells were analyzed by flow cytometry (one-way ANOVA test, n=3–5). *p<0.05. One-way ANOVA test. (E) The tumor-infiltrating IFNγ + CD49b + CD45 + NK cells were analyzed by flow cytometry (one-way ANOVA test, n=3–5). *p<0.05. One-way ANOVA test. (F) The ratio of IFNγ + CD8 + T cells/Foxp3 + Treg cells. *p<0.05. One-way ANOVA test. (G) Gene expression in whole tumors from mice on day 30 after the indicated treatments. Fold-change over isotype control values represented. The results are representative of two independent experiments (n=2 mice per group). (H) Diagram of AAV-IFNβ1, local RT and anti-mouse CD8a antibodies administration protocol. A total of 3×10 5 CT26 cells were subcutaneously injected into the right leg. Local RT was given on days 10 and 13, and AAV (1×10 8 vg in 50 µL PBS, intramuscular injection) was administered on days 9, 13, 16 and 20. Anti-mouse CD8a antibodies were given by intraperitoneal injection (100 µg/mouse). Tumor volume was measured every 2–3 days, and tumors were harvested on day 28 (n=5). **p<0.01, ***p<0.001. (I) The proposed mechanism by which engineered CRC-specific AAV-IFNβ therapy overcomes dysfunctional TLR3-mediated IFN-I attenuation to enhance the response to RT. AAV, adenovirus-associated virus; ANOVA, analysis of variance; RT, radiotherapy.

Journal: Journal for Immunotherapy of Cancer

Article Title: Colorectal cancer-specific IFNβ delivery overcomes dysfunctional dsRNA-mediated type I interferon signaling to increase the abscopal effect of radiotherapy

doi: 10.1136/jitc-2023-008515

Figure Lengend Snippet: Cancer-intrinsic IFNβ1 expression by AAV transduction significantly reshaped cancer immunogenicity to enhance RT-induced immunity. (A) The tumor-infiltrating CD8 + CD3 + CD45 + T cells were analyzed by flow cytometry (one-way ANOVA test, n=3–5). *p<0.05, **p<0.01. One-way ANOVA test. (B) The tumor-infiltrating CD44 + CD62L - CD8 + CD3 + CD45 + T EM cells were analyzed by flow cytometry (one-way ANOVA test, n=3–5). *p<0.05, **p<0.01. One-way ANOVA test. (C) The tumor-infiltrating CD11c + MHC-II+ DCs were analyzed by flow cytometry (one-way ANOVA test, n=3–5). *p<0.05, **p<0.01. One-way ANOVA test. (D) The tumor-infiltrating IFNγ + CD8 + CD3 + CD45 + T cells were analyzed by flow cytometry (one-way ANOVA test, n=3–5). *p<0.05. One-way ANOVA test. (E) The tumor-infiltrating IFNγ + CD49b + CD45 + NK cells were analyzed by flow cytometry (one-way ANOVA test, n=3–5). *p<0.05. One-way ANOVA test. (F) The ratio of IFNγ + CD8 + T cells/Foxp3 + Treg cells. *p<0.05. One-way ANOVA test. (G) Gene expression in whole tumors from mice on day 30 after the indicated treatments. Fold-change over isotype control values represented. The results are representative of two independent experiments (n=2 mice per group). (H) Diagram of AAV-IFNβ1, local RT and anti-mouse CD8a antibodies administration protocol. A total of 3×10 5 CT26 cells were subcutaneously injected into the right leg. Local RT was given on days 10 and 13, and AAV (1×10 8 vg in 50 µL PBS, intramuscular injection) was administered on days 9, 13, 16 and 20. Anti-mouse CD8a antibodies were given by intraperitoneal injection (100 µg/mouse). Tumor volume was measured every 2–3 days, and tumors were harvested on day 28 (n=5). **p<0.01, ***p<0.001. (I) The proposed mechanism by which engineered CRC-specific AAV-IFNβ therapy overcomes dysfunctional TLR3-mediated IFN-I attenuation to enhance the response to RT. AAV, adenovirus-associated virus; ANOVA, analysis of variance; RT, radiotherapy.

Article Snippet: HCT116 cells were treated with 2.5 μg/mL poly (I:C) (Sigma, Missouri, USA) or 10 μM selective TLR3 inhibitor CU-CPT4a (Tocris, Pennsylvania, USA) for 24 hours.

Techniques: Expressing, Transduction, Immunopeptidomics, Flow Cytometry, Gene Expression, Control, Injection, Virus

Review

Structured Review

Images

1) Product Images from "Amino acid restriction sensitizes lung cancer cells to ferroptosis via GCN2-dependent activation of the integrated stress response"

Similar Products

Image Search Results